“R-Pharm” will conduct a clinical study of the drug for the treatment of coronavirus

The Ministry of health of the Russian Federation issued a permit to conduct a clinical trial of the efficacy and safety of olokizumab (inhibitor of interleukin-6) and RPH-104 (inhibitor of interleukin-1) in the treatment of patients with severe infection COVID-19, reported the press service of “R-Pharm”.

Blocking interleukin-1 (IL-1) and interleukin-6 (IL-6) by means of biological drugs are used for pathogenetic therapy of a wide spectrum of hereditary autoinflammatory diseases, rheumatoid arthritis, giant cell arteritis, and cytokine storm.

The study will take place in the Institute of emergency care. N. In. Sklifosovsky Clinical hospital of infectious diseases them. S. P. Botkin in Saint-Petersburg city clinical hospital No. 40 in Kommunarka and city clinical hospital No. 52 in Moscow. Further studies will be connected and other Russian centers.

“Preliminary data from different countries indicate that the blocking of the immune hyperactivation in the levels of IL-1 or IL-6 may be effective in the treatment of patients with severe coronavirus infection, stabilize their condition, lead to further positive dynamics due to the suppression or prevention of cytokine storm,” – said the Director of the medical Department of “R-Pharm” Mikhail Samsonov.

Leave a Reply

Your email address will not be published. Required fields are marked *


For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]